Endothelial dysfunction as a predictor of hypercoagulable disorders in patients with COPD

<b>Purpose:</b> To determine the level of endothelial dysfunction, by determining the activity of von Willebrand factor(VWF) and to determine the relationship with hypercoagulation. <b>Material and methods:</b> 65 patients diagnosed with COPD according to GOLD (2016), determined the markers of coagulation and endothelial dysfunction: fibrinogen, soluble fibrin monomeric complexes(SFMC), D-dimer and VWF. <b>Results:</b> The results of our study noted that an increase in VWF as a marker of endothelial dysfunction and a coagulation stimulator was observed in patients with COPD in 42 of 65 patients (64.6% of cases), including a moderate increase in 19.1% of patients with COPD (on average 109, 6 ± 0.31%), a pronounced increase in 14.3% of patients with COPD (on average 115.8 ± 1.6%), a sharp increase in 50% (on average 132.6 ± 1.5%) and a pronounced increase in VWF, accounting for on average 152.3 ± 1.9% in 16.7% of patients with COPD. The results of the study noted that an increase in the severity of VWF violation (from moderate to a pronounced level) is accompanied by a unidirectional increase in the levels of coagulation markers: fibrinogen from 4.76 ± 0.19 g / l to 7.3 ± 0.25 g / l, SFMC - from 8.9 ± 0.54 mg / 100 ml to 11.8 ± 1.25 mg / 100 ml, D-dimer - 98.3 ± 0.46 ng / ml to 111.8 ± 2.3 ng /ml . An assessment of the direction of the hemocoagulation process in patients with COPD showed that, in cases with a pronounced, sharp and pronounced increase of VWF, observed a 100% increase of fibrinogen, SFMC and D-dimer levels. <b>Conclusion:</b> Endothelial dysfunction is the leading mechanism for stimulating the coagulation cascade in patients with COPD, which increases the risk of thrombosis in this group of patients.

Перевод пока недоступен